Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (211-220 of 272) with videos related to

Pageof 28
Sort By:
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Joachim Sieper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 10, 2020
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III StudyAtul Deodhar, Ricardo Blanco, Eva Dokoupilová, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
RMD Open|January 31, 2025
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extensionAtul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, et al.
The Journal of Rheumatology|June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 StudiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
The Patient|June 29, 2022
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 StudyAna-Maria Orbai, Laura C Coates, Atul Deodhar, et al.
Annals of the Rheumatic Diseases|April 28, 2021
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled studyAtul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Pageof 28

Showing results (211-220 of 272) with videos related to

Sort By:
Pageof 28
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Joachim Sieper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 10, 2020
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III StudyAtul Deodhar, Ricardo Blanco, Eva Dokoupilová, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
RMD Open|January 31, 2025
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extensionAtul Deodhar, Victoria Navarro-Compán, Denis Poddubnyy, et al.
The Journal of Rheumatology|June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 StudiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|July 11, 2013
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisDaniel E Furst, Jonathan Kay, Mary Chester Wasko, et al.
The Patient|June 29, 2022
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 StudyAna-Maria Orbai, Laura C Coates, Atul Deodhar, et al.
Annals of the Rheumatic Diseases|April 28, 2021
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled studyAtul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Pageof 28